The central importance of insulin resistance in the pathophysiology of
polycystic ovary syndrome (PCOS) has been established by pioneering and
elegant studies. In addition to the known hormonal and reproductive
abnormalities that characterize this syndrome, metabolic disorders, as
well as morbidities such as the enhanced risk for type 2 diabetes and
increased risk for cardiovascular disease, have also been demonstrated.
Current therapeutic approaches justifiably include insulin-sensitizing
agents promising to comfort women with PCOS. Management with insulin
sensitizers appears to embrace beneficially in a global fashion several
aspects of the syndrome and target most of the associated metabolic and
reproductive consequences
